Provectus Biopharmaceuticals, Inc. has 3 Schedule 13D or 13G filings on record since 2025-12-01. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Pershing Edward | 11.61% | 52,441,275 | SCHEDULE 13D/A, 2026-07-22 | 2026-06-30 |
| Dominic Rodrigues | 5.67% | 25,220,549 | SCHEDULE 13D, 2025-12-08 | 2025-12-02 |
Purpose of Transaction (Item 4)
Dominic Rodrigues
The Reporting Person acquired the securities for investment purposes. In his capacity as a director and executive officer of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the Issuer's Insider Trading Policy, the Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances. Except as described herein, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person may, from time to time, purchase additional securities of the Issuer either in the open market or in privately-negotiated transactions, depending upon the Reporting Person's evaluation of the Issuer's business, prospects and financial condition, the market for such securities, other opportunities available to the Reporting Person, general economic conditions, stock market conditions and other factors. Depending upon the factors noted above, the Reporting Person may also decide to hold or dispose of all or part of his investments in securities of the Issuer.Item 4 of the SCHEDULE 13D filed 2025-12-08
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-01 | Pershing Edward | 10.56% | SCHEDULE 13D/A |
| 2025-12-08 | Dominic Rodrigues | 5.67% | SCHEDULE 13D |
| 2026-07-22 | Pershing Edward | 11.61% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Provectus Biopharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.